Answers are grounded in this paper and cite their sources.
Estimates of the burden of nonalcoholic fatty liver disease (NAFLD) in the general population are limited because of the lack of sensitivity/specificity of the tests used (liver enzymes and/or hepatic ultrasound) to diagnose NAFLD1. The Fatty Liver Index (FLI) is an algorithm combining body mass index, waist circumference, gamma-glutamyltransferase (GGT) and triglyceride levels that was originally developed in a population residing in Northern Italy to predict the presence of NAFLD.2 Overall, the performance of FLI for the diagnosis of NAFLD is satisfactory in cohorts of Caucasian ethnicity,3-5 but it is of limited value in Asian populations as the risk factors for NAFLD are different between the two populations (Table 1).6, 7 In a recent issue of AP&T, Ruhl and Everhart8 evaluated the performance of FLI in a multiethnic cohort from the USA, which is representative of its population. They examined the performance of FLI both cross-sectionally (to assess its performance to diagnose NAFLD) and longitudinally (to estimate changing trends in the incidence of NAFLD). The authors derived a new algorithm, the US FLI (including age, ethnicity, waist, GGT, insulin and glucose) that performed slightly better than FLI in the prediction of NAFLD by ultrasound (AUC 0.80, CI: 0.77–0.83). Using the US FLI, the authors demonstrated a remarkable increase in the prevalence of NAFLD over the last two decades in the USA.6 The main question is the reliability of FLI and its applicability as a tool to diagnose NAFLD in a clinical setting beyond its use in epidemiologic studies. FLI has been repeatedly validated against ultrasound, which itself has a poor sensitivity especially when the liver fat content <25%.7, 8 Although ultrasound is commonly used to diagnose NAFLD; only MR spectroscopy (MRS) and MR-determined proton density-fat fraction can accurately quantify hepatic steatosis.9 10 To fill this gap, a recent comparison with MRS has shown a good accuracy of FLI in predicting the presence but not the degree of liver fat.11 Thus, FLI is an important tool in epidemiological studies, particularly when assessing the incidence of NAFLD – and this study confirms that we are facing a ‘NAFLD pandemic’ in the near future. However, the applicability of FLI in the clinical setting is limited, particularly if it requires to include insulin, which is not a ‘routine’ test. The clinicians need to identify NAFLD patients, to prevent metabolic, cardiovascular and renal complications, but most importantly to differentiate those with NASH and especially those with advanced fibrosis. Although FLI can help in the detection of fatty liver, it should not be used as a tool to identify presence of NASH. Declaration of personal and funding interests: E. Bugianesi has served as a consultant for GENFIT and IBI.
No takes yet. Share an insight, caveat, or question.
Vanni et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: